Can people with diabetes take Wegovy for weight loss?

Type 2 diabetes: where Wegovy has a clear place

For adults living with type 2 diabetes, Wegovy sits squarely within its UK licence. NICE's appraisal of semaglutide for weight management (TA875) explicitly includes people with weight-related comorbidities such as type 2 diabetes, provided they meet the BMI criteria and are seen within an appropriate clinical setting. Weight loss in type 2 diabetes can improve blood glucose control, reduce the need for some medicines over time, and lower cardiovascular risk, all of which make the clinical rationale stronger, not weaker.

That said, a prescriber reviewing your case will look closely at your current diabetes medicines. Insulin and sulphonylureas (such as gliclazide) can cause low blood sugar even without semaglutide in the mix; adding a medicine that slows gastric emptying and reduces appetite changes the equation. Dose reductions in those medicines are sometimes needed before or shortly after starting Wegovy. This isn't a reason to avoid it, it's a reason to make sure your GP or diabetes team is in the loop from the start. If you're curious about the broader picture of semaglutide and type 2 diabetes, we've covered that in detail separately.

Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance, so the eligibility calculation isn't identical for everyone. A prescriber weighs all of it together.

Type 1 diabetes: a genuinely different situation

Type 1 diabetes is not the same condition as type 2, and the regulatory position reflects that. Wegovy is not licensed for people with type 1 diabetes, and the clinical evidence in this group is far thinner. There are theoretical concerns around diabetic ketoacidosis risk, and the absence of robust trial data means most UK clinicians would not initiate semaglutide for weight loss in someone with type 1 without specialist involvement and very careful monitoring.

That doesn't mean it is never considered, but it does mean the decision belongs firmly with a diabetes specialist, not an online consultation alone. Our prescribers follow NICE guidance and the SmPC, and a situation that falls outside the licensed indication is handled with appropriate caution. If you want a fuller account of the evidence and the specific questions to raise with your specialist, the page on type 1 diabetes and Wegovy covers exactly that.

For context on how semaglutide produces weight loss in the first place, this explanation of the mechanism covers the GLP-1 pathway in plain terms, and if you want to understand how semaglutide is used for weight loss in people without diabetes, we've covered that separately too.

Side effects that matter more when you have diabetes

Wegovy's most common side effects are gastrointestinal: nausea, changes in bowel habits, indigestion and fatigue are typical, especially around dose increases. For most people these are manageable and ease with time. The NHS's patient information on semaglutide sets out the full side-effect profile clearly.

When diabetes is part of the picture, two additional areas deserve attention. First, the blood-sugar interactions with insulin and sulphonylureas described above. Second, if you experience severe, persistent stomach pain that radiates to your back (with or without vomiting) seek urgent medical help. The MHRA highlighted acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines in a Drug Safety Update, and this applies across the class. Gallbladder symptoms and dehydration from prolonged GI illness are also worth knowing about.

None of this is meant to alarm. It is meant to make clear that monitoring matters, especially in the first months, and that staying in contact with both your prescriber and your diabetes team is sensible practice rather than overcaution. Our Wegovy overview covers the full side-effect landscape for anyone who wants to read it before deciding.

How to move forward if you think Wegovy might be right for you

The honest summary is this: if you have type 2 diabetes and meet the BMI criteria, Wegovy is within its licensed remit and is an option worth discussing. If you have type 1, a specialist consultation is the right first step before anything else. Either way, the decision is a clinical one, made by a prescriber who can see your full picture, not one made from a checklist.

At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day. Your diabetes status, current medicines and other health details are all reviewed before any prescription is issued. If you'd like to understand the cost of Wegovy as a private prescription or explore what's included in our service, that information is there when you're ready. When you are, the right place to start is a free consultation with our clinical team, no commitment, just a proper clinical assessment. You can also read more about the weight-loss treatments we offer if you'd like to compare options first.